{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:13:19Z","timestamp":1762431199507,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/jhh.2016.54","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T09:23:29Z","timestamp":1470907409000},"page":"178-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Blood pressure-lowering effects of nifedipine\/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial"],"prefix":"10.1038","volume":"31","author":[{"name":"for the DISTINCT Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Mancia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Gil-Extremera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-7277","authenticated-orcid":false,"given":"G","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S E","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"key":"BFjhh201654_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/VHRM.S11235","volume":"7","author":"WC Tsai","year":"2011","unstructured":"Tsai WC . Treatment options for hypertension in high-risk patients. Vasc Health Risk Manag 2011; 7: 137\u2013141.","journal-title":"Vasc Health Risk Manag"},{"key":"BFjhh201654_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281\u20131357.","journal-title":"J Hypertens"},{"key":"BFjhh201654_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","volume":"42","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050\u20131065.","journal-title":"Hypertension"},{"key":"BFjhh201654_CR4","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","volume":"100","author":"SM Grundy","year":"1999","unstructured":"Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134\u20131146.","journal-title":"Circulation"},{"key":"BFjhh201654_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A . Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603\u2013615.","journal-title":"JAMA"},{"key":"BFjhh201654_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2337\/dc12-0284","volume":"36","author":"PJ O'Connor","year":"2013","unstructured":"O'Connor PJ, Vazquez-Benitez G, Schmittdiel JA, Parker ED, Trower NK, Desai JR et al. Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes. Diabetes Care 2013; 36: 322\u2013327.","journal-title":"Diabetes Care"},{"key":"BFjhh201654_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","volume":"32","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3\u201315.","journal-title":"J Hypertens"},{"key":"BFjhh201654_CR8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1097\/01.ASN.0000071512.93927.4E","volume":"14","author":"XR Huang","year":"2003","unstructured":"Huang XR, Chen WY, Truong LD, Lan HY . Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738\u20131747.","journal-title":"J Am Soc Nephrol"},{"key":"BFjhh201654_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0002-9149(97)89421-0","volume":"79","author":"JR Sowers","year":"1997","unstructured":"Sowers JR . Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. Am J Cardiol 1997; 79: 24\u201328.","journal-title":"Am J Cardiol"},{"key":"BFjhh201654_CR10","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1185\/03007990802262457","volume":"24","author":"JM Neutel","year":"2008","unstructured":"Neutel JM . Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008; 24: 2389\u20132401.","journal-title":"Curr Med Res Opin"},{"key":"BFjhh201654_CR11","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1097\/HJH.0000000000000331","volume":"32","author":"SE Kjeldsen","year":"2014","unstructured":"Kjeldsen SE, Sica D, Haller H, Cha G, Gil-Extremera B, Harvey P et al. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. J Hypertens 2014; 32: 2488\u20132498.","journal-title":"J Hypertens"},{"key":"BFjhh201654_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF . Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30\u201348.","journal-title":"Ann Intern Med"},{"key":"BFjhh201654_CR13","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","volume":"21","author":"JA Whitworth","year":"2003","unstructured":"Whitworth JA . 2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983\u20131992.","journal-title":"J Hypertens"},{"key":"BFjhh201654_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1751-7176.2009.00098.x","volume":"11","author":"TW Littlejohn III","year":"2009","unstructured":"Littlejohn TW III, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11: 207\u2013213.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFjhh201654_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"T Philipp","year":"2007","unstructured":"Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563\u2013580.","journal-title":"Clin Ther"},{"key":"BFjhh201654_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1751-7176.2011.00437.x","volume":"13","author":"MR Weir","year":"2011","unstructured":"Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ III, Graff A, Shojaee A et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +\/\u2212 hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13: 404\u2013412.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFjhh201654_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461\u2013470.","journal-title":"Ann Intern Med"},{"key":"BFjhh201654_CR18","unstructured":"National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. National Kidney Foundation. \n                    http:\/\/www2.kidney.org\/professionals\/KDOQI\/guidelines_ckd\/p4_class_g1.htm\n                    \n                  . Accessed 2 February 2016."},{"key":"BFjhh201654_CR19","unstructured":"National Institutes of Health. High Blood Cholesterol: What You Need To Know. NIH USA. \n                    http:\/\/www.nhlbi.nih.gov\/health\/resources\/heart\/heart-cholesterol-hbc-what-html\n                    \n                  . Accessed 2 February 2016."},{"key":"BFjhh201654_CR20","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S0735-1097(99)00387-3","volume":"34","author":"SM Grundy","year":"1999","unstructured":"Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V . AHA\/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34: 1348\u20131359.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201654_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105\u20131187.","journal-title":"J Hypertens"},{"key":"BFjhh201654_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507\u2013520.","journal-title":"JAMA"},{"key":"BFjhh201654_CR23","first-page":"391","volume":"1","author":"T Arai","year":"2008","unstructured":"Arai T, Ohashi H . Angiotensin receptor blockers and microalbuminuria in hypertensive patients with early (microalbuminuric) stage diabetic nephropathy. Mol Med Rep 2008; 1: 391\u2013393.","journal-title":"Mol Med Rep"},{"key":"BFjhh201654_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10157-008-0040-y","volume":"12","author":"Y Tamura","year":"2008","unstructured":"Tamura Y, Kosuga M, Yamashita M, Tomioka S, Sasaki M, Hikita T et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clin Exp Nephrol 2008; 12: 256\u2013263.","journal-title":"Clin Exp Nephrol"},{"key":"BFjhh201654_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/diacare.26.1.150","volume":"26","author":"K Rossing","year":"2003","unstructured":"Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH . Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 2003; 26: 150\u2013155.","journal-title":"Diabetes Care"},{"key":"BFjhh201654_CR26","first-page":"165","volume":"3","author":"RE F\u00e9ghali","year":"2007","unstructured":"F\u00e9ghali RE, Nisse-Durgeat S, Asmar R . Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. Vasc Health Risk Manag 2007; 3: 165\u2013171.","journal-title":"Vasc Health Risk Manag"},{"key":"BFjhh201654_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/HJH.0b013e328342ef04","volume":"29","author":"G Mancia","year":"2011","unstructured":"Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM . Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens 2011; 29: 600\u2013609.","journal-title":"J Hypertens"},{"key":"BFjhh201654_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0149-2918(04)80049-3","volume":"26","author":"G Derosa","year":"2004","unstructured":"Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E, Ciccarelli L et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004; 26: 1228\u20131236.","journal-title":"Clin Ther"},{"key":"BFjhh201654_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.HYP.0000057420.27692.AD","volume":"41","author":"G Mancia","year":"2003","unstructured":"Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431\u2013436.","journal-title":"Hypertension"},{"key":"BFjhh201654_CR30","first-page":"490769","volume":"2010","author":"HL Elliott","year":"2011","unstructured":"Elliott HL, Lloyd SM, Ford I, Meredith PA . Improving blood pressure control in patients with diabetes mellitus and high cardiovascular risk. Int J Hypertens 2011; 2010: 490769.","journal-title":"Int J Hypertens"},{"key":"BFjhh201654_CR31","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417\u20132428.","journal-title":"N Engl J Med"},{"key":"BFjhh201654_CR32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","volume":"375","author":"GL Bakris","year":"2010","unstructured":"Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173\u20131181.","journal-title":"Lancet"},{"key":"BFjhh201654_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","volume":"56","author":"MA Weber","year":"2010","unstructured":"Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56: 77\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201654_CR34","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0008-6363(01)00388-1","volume":"53","author":"JE Roeters van Lennep","year":"2002","unstructured":"Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE . Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 53: 538\u2013549.","journal-title":"Cardiovasc Res"},{"key":"BFjhh201654_CR35","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769\u20131818.","journal-title":"Eur Heart J"},{"key":"BFjhh201654_CR36","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149\u20131158.","journal-title":"Lancet"},{"key":"BFjhh201654_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/jhh.2008.157","volume":"23","author":"A de la Sierra","year":"2009","unstructured":"de la Sierra A . Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009; 23: 503\u2013511.","journal-title":"J Hum Hypertens"},{"key":"BFjhh201654_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF03261835","volume":"12","author":"D Caldeira","year":"2012","unstructured":"Caldeira D, David C, Sampaio C . Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2012; 12: 263\u2013277.","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhh201654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhh201654","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhh201654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:36:54Z","timestamp":1684431414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFjhh201654"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2016.54","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"type":"print","value":"0950-9240"},{"type":"electronic","value":"1476-5527"}],"subject":[],"published":{"date-parts":[[2016,8,11]]},"assertion":[{"value":"7 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G Mancia has received speaker's or consultation fees in the last 2 years from Actavis, Bayer, B\u00f6hringer Ingelheim, Covidien, CVRx, Daiichi Sankyo, Ferrer, Lilly, Medtronic Vascular Inc., Menarini Int., Merck Serono, MSD, Novartis, Recordati, Sanofi, Servier, Takeda. AJ Lewin has received research grants in the last 2 years from Abbott Laboratories, AbbVie Inc., ActivX Biosciences Inc., Akros Pharma, Inc., Amarin Pharma, Inc., Amgen Inc., Amylin Pharmaceuticals, AstraZeneca, Bavarian Nordic, Bayer, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Catabasis, Daiichi Sankyo, Elcelyx Therapeutics, Eli Lilly and Company, Esperion Therapeutics, Forest Research Institute, Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche, Incyte Corporation, Idenix Pharmaceuticals, Isis Pharmaceuticals, Inc., InteKrin Therapeutics, Inc., Kowa Research Institute, Inc., Merck & Co., Inc., Metabolic Solutions Development Company, N-Gene Pharmaceuticals, Novartis Pharmaceuticals Corp., Novo Nordisk, Omthera Pharmaceuticals Inc., Pfizer Inc., Pharmacopeia, Inc., PhaseBio Pharmaceuticals, Phenomix Corporation, Pronova, Sanofi-Aventis, Sanofi Pasteur, Schering-Plough, Shionogi Inc., Surface Logix, Takeda Pharmaceuticals USA, Inc., Theracos, Inc., TransTech Pharma LLC, TWI Biotechnology, Inc., VIVUS, Inc. and XOMA, LLC. P Harvey has received research grants from AstraZeneca, Merck, Pfizer, Boehringer Ingelheim, Bayer, Ipsen, Sanofi Aventis, Novo Nordisk, Novartis, Takeda, Mitsubushi, Solvay, GlaxoSmithKline, Lilly, Lundbeck, Mundi Pharma, Proctor and Gamble Co and Jannsen. SE Kjeldsen has received lecture honoraria from Bayer, Merck Sharp & Dohme, and Takeda, and honoraria for consulting from Bayer and Takeda. G Cha, B Gil-Extremera, and G Villa declare \u2018none\u2019. Data collection, analysis and manuscript preparation were sponsored by Bayer HealthCare AG. Editorial assistance was provided by Bill Wolvey of PAREXEL International, which was contracted by the study sponsor (Bayer HealthCare AG).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}